These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 30689085)

  • 1. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
    Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
    Sandner P
    Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P; Becker-Pelster EM; Stasch JP
    Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
    Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P; Stasch JP
    Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension.
    Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
    Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
    Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
    Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
    J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
    Cordwin DJ; Berei TJ; Pogue KT
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble GC stimulators and activators: Past, present and future.
    Sandner P; Follmann M; Becker-Pelster E; Hahn MG; Meier C; Freitas C; Roessig L; Stasch JP
    Br J Pharmacol; 2024 Nov; 181(21):4130-4151. PubMed ID: 34600441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble guanylate cyclase stimulators and their potential use: a patent review.
    Sandner P; Vakalopoulos A; Hahn MG; Stasch JP; Follmann M
    Expert Opin Ther Pat; 2021 Mar; 31(3):203-222. PubMed ID: 33395323
    [No Abstract]   [Full Text] [Related]  

  • 20. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.